Article Type
Review
Published
This article reviews the therapeutic landscape in myelofibrosis, which has
significantly improved, and emerging drugs with different
target pathways, alone or in combination with ruxolitinib.
promising.
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.